Digoxin for atrial fibrillation: good, but not too good: a case report

Ranolazine for Atrial Fibrillation: Too Good to be True?

Several management options for patients with symptomatic atrial fibrillation (AF) available today were not even in the realm of discussion two decades ago. These advances, however, have primarily involved invasive management options for patients with drug refractory arrhythmia.1-3 After the recognition that electrical isolation of the thoracic veins benefits patients with paroxysmal AF, a slew ...

GMOs: A Good but Battered Means for Sustainable Production Intensification

FAO promotes Sustainable Production Intensification (SPI), which consists of a technology menu for optimizing crop production per unit area, taking into consideration the range of sustainability aspects including potential and/or real social, political, economic and environmental impacts. The author suggests that Genetically Modified Organism (GMO) cropping is not only well aligned to SPI but a...

Commentary: Good, but not perfect.

relevant standard of success in assisted reproduction? Is there a single “parameter of excellence”? Hum Reprod 2004;19:1052-4. 22 Daya S. Pitfalls in the design and analysis of efficacy trials in subfertility. Hum Reprod 2003;18:1005-9. 23 White A, Hayhoe S, Hart A, Ernst E. Adverse events following acupuncture: prospective survey of 32 000 consultations with doctors and physiotherapists. BMJ 2...

Progress in inflammatory myopathies: good but not good enough.

New Oral Anticoagulants: Good but Not Good Enough!

In the recent article by the European Society of Cardiology Working Group on anticoagulants in heart disease (1), the authors describe in great clarity the emerging data regarding new anticoagulants for the treatment of nonvalvular atrial fibrillation. In the closing segment of conclusions and implications, the authors list their concerns regarding “scientific knowledge gaps” and the lack of cl...